Welcome to GATC - Your Platform to showcase your science

• An individual may be first (presenting) author of only one abstract.
• The presenting author’s name should be the first name to appear in the author listing.
• The first (presenting) author must present the study in terms of high throughput genomics/proteomics/metabolomics or single cell & spatial genomics experiments conducted during the course of the project. Authors who do not conform to this policy at the meeting will be subject to disqualification as determined by the Program Committee.
• There is no limit to the number of times an individual may appear as co-author on abstracts.
• Co-authors do not receive communication related to the abstract. First authors are responsible for coordinating communication with co-authors.

• I have read, understand, and agree to the Abstract Submission Rules and Meeting Policies, including Code of Conduct.
• I understand that in submitting an abstract, I am authorizing GATC to contact me about its Annual Meeting, including the status of my abstract.
• I will submit only one abstract as first author. I understand I can only speak and moderate for one accepted proposal. This includes if I have been accepted as an invited session speaker.
• I understand that as first author, I must notify all authors of any and all correspondence relating to this abstract submission.
• I confirm that each co-author has been informed of this abstract submission and has agreed to all information as it was submitted.
• I verify that any reported human participants research was conducted with participants’ voluntary, informed consent, with approval by an appropriate research ethics committee, and consistent with the principles of research ethics. 
• I am submitting this abstract with the intent of attending and presenting my work in person at the Genomics Analysis & Technology Conference being held from 4th till 6th April 2025, at IISER Pune, Maharashtra, India. I understand that if I do not register and attend in person, my abstract may be withdrawn and my opportunity to present in IISER Pune will be forfeited. I understand that GATC is not making any commitments to host virtual, or hybrid content formats and reserves the right, at its sole discretion, to make adjustments to presentation format and style.
• Presenting Author Disclosure: If my abstract is accepted as a platform or plenary (oral) presentation, I understand that I must include a conflict-of-interest slide as part of my presentation and that I must provide verbal and written disclosures to attendees.
• Presenting Author Disclosure: If my abstract is accepted as a platform or plenary (oral) presentation, I agree to use generic names (i.e., non-branded names) in my presentation as much as possible. Specific products of ineligible companies will neither be promoted nor disparaged. The content of my presentation will not contain advertisements for a specific product, company, and/or service nor contain any logos of an ineligible company. In addition, I agree to disclose on the required disclosure slide any unlabeled/unapproved uses of drugs or products referenced in my presentation/materials. 

A major goal of GATC 2025 is to showcase leading edge research that is new to the field and appears in an international forum for the first time. If the findings in this abstract submission have been or will be published elsewhere prior to 31st March 2025, authors should make clear what new information will be presented.

• It is the authors’ responsibility to update the submission concerning any acceptances that occur before the submission deadline of February 15th.
• For abstracts that are previously published, authors are strongly encouraged to describe any advancement beyond published work that will be presented.
• At time of assigning platform talks, the Program Committee will independently verify whether there is a publication available with an acceptance date before March 31. Failure to disclose prior publication will result in abstracts being deprioritized for oral presentation in plenary or platform sessions.

For purposes of this policy, “previously published” means:

1. Accepted for peer-reviewed publication, or
2. Accepted for oral presentation at other conferences

Material posted on a preprint server is NOT considered previously published.

After the February 15 deadline, abstracts will be reviewed by the Scientific Committee (SC). The Committee programs abstract as follows:

• Abstracts are reviewed to ensure they have been submitted to the correct topic category. If not, the abstract is moved to a more appropriate topic, where it can be reviewed by appropriate experts.
• Each abstract is reviewed by four SC reviewers.
• This review step is blinded and strictly confidential. Each reviewer scores the abstracts independently, without knowledge of the name(s) and institution(s) of the submitter(s) or the scores given by the other reviewers.
• In October, the Scientific Committee meets to assign abstracts to Platform and Poster Sessions based on the cumulative score as well as the impact of the science and the balance of topics for GATC’s multi-platform audience.
  • Approximately 5-6 abstracts are selected for oral GATC-Young Scientist Award Session.
  • Approximately 50 accepted abstracts are assigned to posters, and the top-scoring poster abstracts are awarded the Reviewer's Best Poster's designation.
• The Scientific Committee reserves the right to decline a presentation to any submitted abstracts that lack scientific content or merit or that merely announce the availability of a resource or service.
• Abstract acceptance notifications will be sent to authors in March. Abstracts are programmed into the following session types:
  • GATC Young Scientist Award
  • Poster Sessions
    • Reviewer’s Best Poster Recognition

ABSTRACT TITLE:

Title should follow sentence case format: Human Genomics is great: NGS Analysis of disease cases confirms enormous potential of the field.

• Title should begin with a capital letter and should have a period at the end (unless you have other punctuation, such as a question mark). Do not use all caps. Abstracts with titles in ALL CAPS may not be reviewed. Maximum 300 words (including spaces).
  • Only use additional capital letters as appropriate (e.g., Transcriptome analysis using Next Generation Sequencing; or Evidence of the XYZ mutation found in cancer patients with normal WES analysis.).
• For gene/protein designations, please follow these guidelines set by The American Journal of Human Genetics: Human gene names and loci should be written in italicized capital letters and Arabic numerals. Protein product names should not be italicized.
• Please use the italicized button where needed; do not enter special codes for bold or underline for your title. Text will automatically flow to the next line.
• Special Characters: Please prepare your title using a special character, if necessary. 
• When finished with your attestations and title entry, click “Save and Continue.” Your submission will be saved as an in-progress draft at this point. If you need to log out and return to the form later to finish, find the name of this abstract in your drive, click on it to resume your progress.

FIRST (PRESENTING) AUTHOR'S INFORMATION:

• The first (presenting) author cannot be the first author of another abstract being submitted.
• Required information: first and last name, institution, institution city, institution country, mobile phone, email address, contact city, contact country, and additional information questions.
• The first author’s name on a submitted abstract cannot be changed.
  • If you notice that your name is incorrect after payment and completion of the abstract submission, do not withdraw or delete a paid abstract submission to make edits or submit a new abstract. Refunds will not be issued for abstracts that are withdrawn, and payment will be required for any resubmissions. Contact GATC Organizing Team (info@gatc.co.in) for assistance.
  • If the first author has changed, then withdraw the abstract and ask the new first author to re-submit a new abstract by 15th Feb 2025. Note: Refunds will not be issued for abstracts that are withdrawn, and payment will be required for any resubmissions.
• Enter the address and affiliation information in upper and lowercase as it should be published. Do not use special characters in the name or address fields. If applicable, include international dialing codes for phone numbers.
• GATC does not permit co-first author designations.

ABSTRACT TEXT:

• You are allotted 300 words, excluding spaces, for the body of your abstract. Title, author, and institutional data should not be included in the abstract body text. The submission will remain incomplete, and will not be reviewed, if the word limit is exceeded. Words will be counted as you enter your abstract text. Make sure your abstract adheres to the style guide outlined below.
• Click the “Upload Abstract” link and upload your abstract file into the form.
  • Step 1: Prepare your abstract in a program such as Word or a text editor like Notepad/TextEdit. You can submit final abstracts in PDF formats. 
  • Step 2: Save your abstract file with your name, institute name and affiliation and date.
  • Step 3: Click “Upload abstract” to upload the Abstract to the form. Then submit.
• Graphics and halftones cannot be submitted as part of your abstract.
• For gene/protein designations, please follow these guidelines set by The American Journal of Human Genetics: Human gene names and loci should be written in italicized capital letters and Arabic numerals. Protein product names should not be italicized.
• Note: Abstracts are published as submitted. Please check for accuracy before submitting.
• Once you submit your abstract its final and no further edits are allowed. 

ABSTRACT TRACK:

Students/ delegates can submit abstract for posters and oral presentation based on the following areas of human genomics:

• Clinical Genetics/Genomics
• Molecular and cytogenetic diagnostics
• Rare disease diagnostics & therapeutics
• Complex traits and polygenic disorders
• Epigenetics
• Evolutionary and population genetics
• Genetic counselling
• Genetic, genome and epigenome databases and resources
• Molecular effects of genetic variation
• Omics technologies
• Pharmacogenomics
• Prenatal, perinatal and developmental genetics
• Statistical genetics and genetic epidemiology
• Cancer and other critical illness
• Precision Medicine & Therapeutics
• Single Cell & Spatial Genomics

You will be asked to select from the dropdown menu the track that most closely describes the work in your abstract.

Once a track is selected, click “Save and Continue.”